Incumbents vs. challengers: moats, disruption, and the innovator's dilemma

In 2012, Intuitive Surgical sold its da Vinci robot to hospitals for roughly $1.5 million per unit, plus recurring fees on instruments and service. Meanwhile, open-surgery incumbents (the surgeons and the toolmakers who supplied them) held decades of skill, relationships, and trust. Twelve years later, over 12,000 da Vinci systems were installed worldwide (Intuitive company reporting, as of early 2024). The scalpel makers did not lose because their scalpels got worse. They lost because a challenger changed the unit of competition from "the blade" to "the platform."

That is the whole lesson in one scene. Who actually holds power in biotech and medtech, and which moats survive contact with a real challenger?

The two archetypes of disruption

Not all challengers threaten incumbents the same way. Compare two.

The CRISPR startup vs. legacy pharma. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats, a gene-editing tool) lets you edit DNA directly. Companies like Vertex and CRISPR Therapeutics won FDA (US Food and Drug Administration) and EMA (European Medicines Agency) approval in late 2023 for Casgevy, a one-time treatment for sickle cell disease. A one-time cure attacks the razor-and-blades model of chronic drug sales.

The robotic-surgery upstart vs. open surgery. Intuitive did not sell a molecule. It sold a capital device plus a stream of consumables, and it locked in hospitals through training and installed base.

These are different games. In pharma, the moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.View full definition → is molecular and legal. In devices, the moat is physical and behavioral. Understanding which is which tells you which moats actually hold.

Mapping the players

Before you judge power, name the players. In this sector the chain runs:

• Suppliers: CROCROConversion Rate Optimization (CRO) is the systematic practice of increasing the percentage of users who complete a desired action, using data, testing, and user research.View full definition →/CMOs (Contract Research Organizations and Contract Manufacturing Organizations, firms that run trials or make product for you), reagent makers, chip and sensor suppliers.
• Incumbents: big pharma (Pfizer, Roche, Novartis) and big medtech (Medtronic, Stryker, Johnson & Johnson MedTech).
• Challengers: platform biotechs and device startups.
• Distributors and buyers: hospitals, GPOs (Group Purchasing Organizations, US entities that negotiate device prices on behalf of many hospitals), pharmacy benefit managers, national health systems in Europe.
• Regulators and payers: FDA and EMA (approval), plus CMS (Centers for Medicare and Medicaid Services, US) and bodies like NICE (UK) and G-BA (Germany) that decide reimbursement.

Note the split between "approval" and "getting paid." A challenger can win the FDA and still die because no payer reimburses the product. That is a power lever incumbents understand and newcomers underestimate.

Which moats actually hold

Patents: strong in pharma, leakier in devices

A drug patent (typically 20 years from filing, though effective life is shorter after trial time) plus regulatory exclusivity can give a molecule near-total protection. When it expires, generics or biosimilars (near-copies of biologic drugs) crush the price. This is the famous patent cliff: Humira, once the world's top-selling drug, lost US exclusivity in 2023 and faced multiple biosimilars.

In devices, patents matter less. A robot or stapler is a system of hundreds of components. Competitors design around individual claims. The moat is rarely one patent. It is the integrated whole plus everything below.

Installed base and switching costs: the device superpower

Once a hospital buys a da Vinci and trains 20 surgeons on it, switching to a rival robot means retraining, revalidating workflows, and renegotiating service contracts. That is a switching cost moat, and it is durable. New entrants like Medtronic's Hugo and J&J's Ottava have real technology, yet they fight uphill against an installed base and a trained surgeon population.

Lesson: in medtech, the moat is often the customer's own sunk cost, not your IP.

Sales forces and relationships: real but attackable

Big pharma and medtech field thousands of reps with deep hospital relationships. That is why many challengers do not try to build a rival sales force. They get acquired or partner instead. Vertex commercialized Casgevy itself, but many smaller biotechs license their asset to a big player precisely to rent that distribution moat.

Manufacturing and regulatory know-how

For complex biologics and cell therapies, manufacturing IS the moat. Making a personalized cell therapy reproducibly at scale, under GMP (Good Manufacturing Practice, the FDA/EMA quality standard), is brutally hard. That difficulty protects incumbents with plants and protects specialist CMOs who supply everyone.

The innovator's dilemma, biotech edition

Clayton Christensen's core insight: incumbents fail not because they are dumb, but because they are rational. They listen to their best customers and protect their most profitable products. That is exactly what makes them slow to adopt something that threatens those products.

Pharma example. A one-time gene therapy that cures a disease cannibalizes a lucrative chronic-treatment franchise. A rational incumbent is slow to build the thing that kills its own annuity. That hesitation is the opening a challenger exploits.

Device example. Early robotic surgery was more expensive and slower than open surgery, and skeptics were loud. To a leading open-surgery toolmaker, it looked like an inferior, overpriced niche. Classic "disruptive technology": worse on the metrics incumbents value, better on a new metric (minimally invasive, less recovery time) that customers came to value more.

How value and margin are distributed

Follow the money along the chain, because power shows up as who keeps the margin.

• Blockbuster pharma: extremely high gross margins on a patented drug (often cited around 80 to 90 percent gross margingross marginGross margin is the share of revenue left after subtracting the direct cost of producing goods or services, expressed as a percentage of revenue.View full definition →, estimate, varies by product), because the cost is in R&D and trials, not per-pill manufacturing. Value concentrates with the patent holder until the cliff.
• Devices: a large share of lifetime valuelifetime valueLifetime Value: the total revenue (or profit) a customer generates throughout their entire relationship with your business.View full definition → sits in recurring consumables and service, not the one-time hardware sale. This is the razor-and-blades structure, and it favors whoever controls the installed base.
• Suppliers (CROs/CMOs): steady margins, lower volatility, because they get paid regardless of whether the drug wins.
• Payers and GPOs: capture value by squeezing price at the point of reimbursement.

A simple worked example: razor and blades

Suppose a surgical robot sells for $1.5 million (illustrative, not a current quote) and generates $2,000 of consumables and service per procedure. A busy hospital does 300 robotic procedures a year.

Recurring revenue per system per year = 300 x $2,000 = $600,000.

Over a 7-year system life, recurring revenue = 7 x $600,000 = $4.2 million.

So the $1.5 million hardware sale is roughly one quarter of the ~$5.7 million lifetime revenue per system. The margin lives in the blades, not the razor. This is why the installed base moat is so valuable: every locked-in system is a multi-year annuity.

Reading a real battle: how challengers actually win

Patterns that repeat in this sector:

1. Change the unit of competition. Intuitive competed on "platform + workflow," not on blades. CRISPR firms compete on "cure," not on "chronic control."
2. Rent the moat you cannot build. Small biotechs license to big pharma for distribution and manufacturing rather than fight the sales force head-on.
3. Win reimbursement, not just approval. The die-off point for challengers is often the payer, not the FDA. For deeper reading on how European reimbursement works, see the EMA's overview of the medicines lifecycle.
4. Build the switching cost early. Train the users, embed the workflow, and the installed base becomes your defense once incumbents finally respond.

And how incumbents defend:

• Buy the challenger before it scales (very common in both pharma and medtech).
• Fast-follow with a rival platform and use existing hospital relationships to close the gap (Medtronic and J&J in robotics).
• Use patent thickets and litigation to slow entrants, especially in biosimilars.

The uncomfortable truth: the strongest incumbent defense is often acquisition, which is why "disruption" in this sector frequently ends with the challenger inside the incumbent.

Key takeaways

• Moats are asset-specific. In pharma the durable moat is patents plus manufacturing and regulatory know-how. In devices it is the installed base and switching costs, not any single patent.
• The margin lives in the recurring stream. Devices earn most lifetime value from consumables and service; drugs earn it from the patented molecule until the cliff.
• Approval is not access. A challenger can clear the FDA or EMA and still fail at the payer (CMS, NICE, G-BA). Reimbursement is a real power lever.
• The innovator's dilemma is rational. Incumbents hesitate because a cure or a cheaper platform cannibalizes their best business. That hesitation is the challenger's window.
• Most disruption ends in a deal. Watch for acquisition and licensing, because that is how power is most often resolved in biotech and medtech.